HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RYTM
Rhythm Pharmaceuticals, Inc.
There isn't enough reported data to score RYTM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RYTM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RYTM's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RYTM PE Valuation
RYTM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RYTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RYTM has the edge over HIMS on the outlook, with more favorable profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RYTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.90 | +$0.19 |
| Q2 2026 | -$3.11 | -$0.11 |
| Q1 2026 | -$3.13 | -$0.33 |
| Q4 2025 | -$3.11 | +$1.23 |
| Q3 2025 | -$3.09 | +$1.24 |
| Q2 2025 | -$3.00 | +$1.36 |
| Q1 2025 | -$2.80 | +$1.83 |
| Q4 2024 | -$4.34 | -$1.14 |
RYTM has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RYTM on profitability, with a higher operating margin.
RYTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.1M | +80% |
| Q2 2026 | $71.3M | +47% |
| Q1 2026 | $60.1M | +84% |
| Q4 2025 | $57.3M | +37% |
| Q3 2025 | $51.3M | +54% |
| Q2 2025 | $48.5M | +67% |
| Q1 2025 | $32.7M | +26% |
| Q4 2024 | $41.8M | +73% |
RYTM has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -43% | +60 points |
| Q2 2026 | -68% | +25 points |
| Q1 2026 | -87% | +57 points |
| Q4 2025 | -82% | +16 points |
| Q3 2025 | -103% | +29 points |
| Q2 2025 | -93% | +46 points |
| Q1 2025 | -144% | +395 points |
| Q4 2024 | -99% | +72 points |
RYTM's operating margin was −43% last quarter, up 60 points from the same quarter a year ago, near the top of its range since 2021.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
RYTM has the stronger cash trend. Its trailing FCF is up 30% versus its history, compared with HIMS at down 84%.
RYTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | +$14.2M |
| Q1 2026 | -$44.2M | -$3.8M |
| Q4 2023 | -$29.4M | +$4.6M |
| Q3 2023 | -$29.3M | +$17.8M |
| Q2 2023 | -$41.1M | -$2.2M |
| Q1 2023 | -$36.5M | +$17.3M |
| Q4 2022 | -$34M | +$6.5M |
| Q3 2022 | -$47.1M | -$6.8M |
RYTM has burned cash in almost every quarter: −$103M over the past year, against −$140M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RYTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RYTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +453K shares |
| 1 year | +4.2% | +2.8M shares |
| 3 years | +19% | +11.2M shares |
| 5 years | +37% | +18.8M shares |
| Available history | +90% | +32.6M shares |
RYTM has 69M diluted shares, up 4.2% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RYTM Net Leverage
RYTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RYTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 58.5 | Neutral |
RYTM's weekly RSI is 58 (neutral) and its Stochastic is 58 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RYTM PE vs Healthcare Sector
RYTM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RYTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $96.6 | 14% above |
| 20 week MA | $102.8 | 6.8% above |
| 50 week MA | $98.3 | 12% above |
| 100 week MA | $87.0 | 26% above |
| 200 week MA | $61.1 | 80% above |
RYTM has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RYTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.0 | $29.0 | +26% |
| 2021 | $29.0 | $12.2 | -58% |
| 2022 | $12.2 | $29.2 | +139% |
| 2023 | $29.2 | $46.0 | +57% |
| 2024 | $46.0 | $55.6 | +21% |
| 2025 | $55.6 | $110.0 | +98% |
| 2026 YTD | $110.0 | $109.9 | -0.1% |
RYTM has the edge over HIMS on returns for 2026, with the stronger performance.